WCM Investment Management LLC Sells 138,486 Shares of Insmed, Inc. $INSM

WCM Investment Management LLC lowered its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 89.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 15,500 shares of the biopharmaceutical company’s stock after selling 138,486 shares during the period. WCM Investment Management LLC’s holdings in Insmed were worth $2,196,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. EULAV Asset Management acquired a new stake in Insmed in the 3rd quarter valued at $12,961,000. Resolute Capital Asset Partners LLC acquired a new position in Insmed during the second quarter worth $2,748,000. Nisa Investment Advisors LLC lifted its holdings in shares of Insmed by 374.6% during the third quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock valued at $1,507,000 after acquiring an additional 8,261 shares during the period. Calamos Advisors LLC boosted its stake in shares of Insmed by 53.4% in the 3rd quarter. Calamos Advisors LLC now owns 35,215 shares of the biopharmaceutical company’s stock valued at $5,071,000 after purchasing an additional 12,263 shares in the last quarter. Finally, Guggenheim Capital LLC grew its holdings in shares of Insmed by 16.8% in the 2nd quarter. Guggenheim Capital LLC now owns 41,391 shares of the biopharmaceutical company’s stock worth $4,166,000 after purchasing an additional 5,945 shares during the last quarter.

Insider Buying and Selling at Insmed

In other news, Director Elizabeth M. Anderson sold 10,000 shares of Insmed stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the completion of the sale, the director owned 63,729 shares in the company, valued at $12,482,599.23. The trade was a 13.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Leo Lee sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the completion of the transaction, the director directly owned 54,677 shares in the company, valued at approximately $10,711,224.30. The trade was a 57.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 269,669 shares of company stock worth $49,310,335 over the last quarter. Company insiders own 3.00% of the company’s stock.

Insmed Trading Up 2.1%

INSM stock opened at $157.16 on Wednesday. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a market cap of $33.52 billion, a P/E ratio of -25.39 and a beta of 1.11. The business has a fifty day moving average of $178.14 and a 200-day moving average of $159.71.

Analysts Set New Price Targets

INSM has been the subject of several analyst reports. Guggenheim cut their price target on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Royal Bank Of Canada raised their price objective on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. HC Wainwright decreased their price target on Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $206.04.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.